JOP20210266A1 - مثبطات كيناز تيروسين fgfr لمعالجة كارسينوما الظهارة البولية - Google Patents
مثبطات كيناز تيروسين fgfr لمعالجة كارسينوما الظهارة البوليةInfo
- Publication number
- JOP20210266A1 JOP20210266A1 JOP/2021/0266A JOP20210266A JOP20210266A1 JO P20210266 A1 JOP20210266 A1 JO P20210266A1 JO P20210266 A JOP20210266 A JO P20210266A JO P20210266 A1 JOP20210266 A1 JO P20210266A1
- Authority
- JO
- Jordan
- Prior art keywords
- urothelial carcinoma
- fgfr
- treatment
- tyrosine kinase
- kinase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Wood Science & Technology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
Abstract
يتعلق الاختراع الحالي بطرق لمعالجة كارسينوما الظهارة البولية لدى مريض تشمل تقييم عينة بيولوجية من المريض من حيث وجود اثنين على الأقل من التغييرات الجينية لمستقبل عامل نمو أرومة ليفية (FGFR) ومعالجة المريض بمثبط FGFR. ويتعلق الاختراع الحالي أيضًا بطرق لمعالجة كارسينوما الظهارة البولية لدى مريض يضم اثنين على الأقل من التغييرات الجينية لمستقبل عامل نمو أرومة ليفية (FGFR) تشمل إعطاء مثبط FGFR.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19166428 | 2019-03-29 | ||
EP19188971 | 2019-07-30 | ||
PCT/US2020/025166 WO2020205493A1 (en) | 2019-03-29 | 2020-03-27 | Fgfr tyrosine kinase inhibitors for the treatment of urothelial carcinoma |
Publications (1)
Publication Number | Publication Date |
---|---|
JOP20210266A1 true JOP20210266A1 (ar) | 2023-01-30 |
Family
ID=70296138
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JOP/2021/0266A JOP20210266A1 (ar) | 2019-03-29 | 2020-03-27 | مثبطات كيناز تيروسين fgfr لمعالجة كارسينوما الظهارة البولية |
Country Status (14)
Country | Link |
---|---|
US (1) | US20220054484A1 (ar) |
EP (1) | EP3946341A1 (ar) |
JP (1) | JP2022527189A (ar) |
KR (1) | KR20210145211A (ar) |
CN (1) | CN113645974A (ar) |
AU (1) | AU2020253827A1 (ar) |
BR (1) | BR112021019446A2 (ar) |
CA (1) | CA3130460A1 (ar) |
IL (1) | IL286729A (ar) |
JO (1) | JOP20210266A1 (ar) |
MA (1) | MA55522A (ar) |
MX (1) | MX2021011926A (ar) |
SG (1) | SG11202109902SA (ar) |
WO (1) | WO2020205493A1 (ar) |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
US5882864A (en) | 1995-07-31 | 1999-03-16 | Urocor Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
WO2006127926A2 (en) | 2005-05-23 | 2006-11-30 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
US8163923B2 (en) | 2007-03-14 | 2012-04-24 | Advenchen Laboratories, Llc | Spiro substituted compounds as angiogenesis inhibitors |
GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
LT3198033T (lt) | 2014-09-26 | 2022-05-10 | Janssen Pharmaceutica Nv | Fgfr mutantinių genų rinkinių panaudojimas identifikuojant vėžiu sergančius pacientus, kurie reaguos į gydymą fgfr inhibitoriumi |
AU2016341445B2 (en) * | 2015-10-23 | 2020-08-27 | Array Biopharma, Inc. | 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases |
JOP20190190A1 (ar) * | 2017-02-06 | 2019-08-04 | Janssen Pharmaceutica Nv | معالجة سرطان |
JOP20190280A1 (ar) * | 2017-06-02 | 2019-12-02 | Janssen Pharmaceutica Nv | مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية |
-
2020
- 2020-03-27 AU AU2020253827A patent/AU2020253827A1/en active Pending
- 2020-03-27 JO JOP/2021/0266A patent/JOP20210266A1/ar unknown
- 2020-03-27 MX MX2021011926A patent/MX2021011926A/es unknown
- 2020-03-27 CN CN202080025860.4A patent/CN113645974A/zh active Pending
- 2020-03-27 CA CA3130460A patent/CA3130460A1/en active Pending
- 2020-03-27 EP EP20720283.9A patent/EP3946341A1/en active Pending
- 2020-03-27 WO PCT/US2020/025166 patent/WO2020205493A1/en active Application Filing
- 2020-03-27 MA MA055522A patent/MA55522A/fr unknown
- 2020-03-27 US US17/599,729 patent/US20220054484A1/en active Pending
- 2020-03-27 KR KR1020217034721A patent/KR20210145211A/ko active Search and Examination
- 2020-03-27 SG SG11202109902S patent/SG11202109902SA/en unknown
- 2020-03-27 JP JP2021557924A patent/JP2022527189A/ja active Pending
- 2020-03-27 BR BR112021019446A patent/BR112021019446A2/pt unknown
-
2021
- 2021-09-26 IL IL286729A patent/IL286729A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2020253827A1 (en) | 2021-09-30 |
EP3946341A1 (en) | 2022-02-09 |
MA55522A (fr) | 2022-02-09 |
MX2021011926A (es) | 2021-11-03 |
WO2020205493A1 (en) | 2020-10-08 |
IL286729A (en) | 2021-10-31 |
KR20210145211A (ko) | 2021-12-01 |
CN113645974A (zh) | 2021-11-12 |
US20220054484A1 (en) | 2022-02-24 |
BR112021019446A2 (pt) | 2021-11-30 |
JP2022527189A (ja) | 2022-05-31 |
SG11202109902SA (en) | 2021-10-28 |
CA3130460A1 (en) | 2020-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201792191A1 (ru) | Комбинированная терапия fgfr/pd-1 для лечения злокачественной опухоли | |
NI201700035A (es) | Uso de paneles de genes mutantes del fgfr en la identificación de pacientes con cáncer que responderán al tratamiento con un inhibidor del fgfr | |
PH12019502710A1 (en) | Fgfr2 inhibitors for the treatment of cholangiocarcinoma | |
MX2022004937A (es) | Inhibidores de las cinasas raf. | |
MX2023005747A (es) | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos. | |
NO20072179L (no) | Kombinasjon av en SRC kinase inhibitor og en. BCR-ABL inhibitor for behandling av proleferative sykdommer | |
EA201791236A1 (ru) | Применение ингибиторов пан fgfr и способ идентификации пациентов, заболевших раком, для лечения с помощью ингибитора пан fgfr | |
MX2022015410A (es) | Inhibidores de las cinasas receptoras del factor de crecimiento de fibroblastos. | |
CR20230325A (es) | Compuestos de indazol como inhibidores de cinasas | |
MX2021009426A (es) | Derivados de indazolil-isoxazol para el tratamiento de enfermedades tales como cancer. | |
JOP20210260A1 (ar) | مثبطات كيناز تيروسين مستقبل عامل نمو الأرومة الليفية لمعالجة كارسينوما الظهارة البولية | |
MX2020005344A (es) | Compuestos de pirazolopiridinona. | |
JOP20210266A1 (ar) | مثبطات كيناز تيروسين fgfr لمعالجة كارسينوما الظهارة البولية | |
MX2022009905A (es) | Inhibidores de la tirosina?cinasa fgfr para el tratamiento del cancer de vejiga sin invasion muscular de riesgo alto. | |
EA202192656A1 (ru) | Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы | |
MX2021008865A (es) | Inhibidores de magl para usarse para tratar enfermedades antecedentes. | |
EP4097140A4 (en) | USE OF QUINAZOLINE-BASED TYROSINE KINASE INHIBITORS TO TREAT CANCER WITH NRG1 FUSIONS | |
MX2021007853A (es) | Compuestos de tienopiridinona. | |
MX2022009904A (es) | Inhibidores de fgfr tirosina cinasa y agentes anti-pd1 para el tratamiento de carcinoma urotelial. | |
EA202192643A1 (ru) | Ингибиторы тирозинкиназ fgfr для лечения уротелиальной карциномы | |
EA201992036A1 (ru) | Ингибирование smarca2 для лечения рака | |
PH12021550628A1 (en) | Treatment of cholangiocarcinoma | |
EA202092360A1 (ru) | Комбинация ингибиторов lif и ингибиторов оси pd-1 для применения в лечении рака | |
EA202092711A1 (ru) | Способы и композиции для лечения рака | |
AR122377A1 (es) | Inhibidores de fgfr tirosina cinasa y agentes anti-pd1 para el tratamiento de carcinoma urotelial |